ES2164400T3 - Esteroides con actividad anticonceptiva y antiosteoporotica. - Google Patents

Esteroides con actividad anticonceptiva y antiosteoporotica.

Info

Publication number
ES2164400T3
ES2164400T3 ES98200518T ES98200518T ES2164400T3 ES 2164400 T3 ES2164400 T3 ES 2164400T3 ES 98200518 T ES98200518 T ES 98200518T ES 98200518 T ES98200518 T ES 98200518T ES 2164400 T3 ES2164400 T3 ES 2164400T3
Authority
ES
Spain
Prior art keywords
ring
anticonceptive
steroids
steroid
menopause
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98200518T
Other languages
English (en)
Spanish (es)
Inventor
H J J Loozen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2164400T3 publication Critical patent/ES2164400T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0085—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES98200518T 1997-02-21 1998-02-18 Esteroides con actividad anticonceptiva y antiosteoporotica. Expired - Lifetime ES2164400T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97102884 1997-02-21

Publications (1)

Publication Number Publication Date
ES2164400T3 true ES2164400T3 (es) 2002-02-16

Family

ID=8226513

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98200518T Expired - Lifetime ES2164400T3 (es) 1997-02-21 1998-02-18 Esteroides con actividad anticonceptiva y antiosteoporotica.

Country Status (27)

Country Link
US (2) US6077873A (da)
EP (1) EP0869132B1 (da)
JP (1) JP4392066B2 (da)
KR (1) KR19980071540A (da)
CN (2) CN100522984C (da)
AR (1) AR011680A1 (da)
AT (1) ATE205217T1 (da)
AU (1) AU723713B2 (da)
BR (1) BR9800718B1 (da)
CA (1) CA2229960C (da)
CZ (1) CZ50598A3 (da)
DE (1) DE69801539T2 (da)
DK (1) DK0869132T3 (da)
ES (1) ES2164400T3 (da)
HK (1) HK1016188A1 (da)
HU (1) HU223755B1 (da)
ID (1) ID19947A (da)
IL (1) IL123195A (da)
NO (1) NO310724B1 (da)
NZ (1) NZ329789A (da)
PL (1) PL188079B1 (da)
PT (1) PT869132E (da)
RU (1) RU2182153C2 (da)
SG (1) SG60203A1 (da)
TR (1) TR199800282A1 (da)
TW (1) TW403736B (da)
ZA (1) ZA981344B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403736B (en) * 1997-02-21 2000-09-01 Akzo Nobel Nv Steroid compounds having contraceptive and anti-osteoporosis activity
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
ES2204613T3 (es) * 1999-04-06 2004-05-01 Akzo Nobel N.V. Androgenos 7-alfa alquilo oralmente activos.
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
TWI225068B (en) * 2000-06-06 2004-12-11 Akzo Nobel Nv Anellated steroid compounds having contraceptive and anti-osteoporosis activity
JP2002241395A (ja) * 2001-02-16 2002-08-28 Taiho Yakuhin Kogyo Kk エストラ−４，６−ジエン−３，１７−ジオンの製造方法
US7250289B2 (en) 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
JP2010513475A (ja) * 2006-12-20 2010-04-30 ランドシュタイナー サイエンティフィック エッセ アー デ シー ヴイ リセドロネートおよびビタミンｄ組成物
TW201109346A (en) * 2009-06-10 2011-03-16 Organon Nv Substituted 16,17-annellated steroid compounds for use in women's healthcare
US8367648B2 (en) 2009-06-10 2013-02-05 Msd Oss B.V. Substituted 16,17-annellated steroid compounds for use in womens healthcare

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE105299T1 (de) * 1989-08-04 1994-05-15 Schering Ag 11 beta-substituierte 16 alpha, 17alpha-methylen- estra-4,9-dien-3-one.
ES2127181T3 (es) * 1989-08-04 1999-04-16 Schering Ag 11-beta-aril-gona-4,9-dien-3-onas.
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
ZA94715B (en) * 1993-02-08 1994-10-24 Akzo Nv Steroids for treating menopausal complaints
TW403736B (en) * 1997-02-21 2000-09-01 Akzo Nobel Nv Steroid compounds having contraceptive and anti-osteoporosis activity

Also Published As

Publication number Publication date
RU2182153C2 (ru) 2002-05-10
JPH10273499A (ja) 1998-10-13
PT869132E (pt) 2002-01-30
NO310724B1 (no) 2001-08-20
ZA981344B (en) 1998-08-27
NO980737L (no) 1998-08-24
PL188079B1 (pl) 2004-12-31
HUP9800373A2 (hu) 1998-11-30
EP0869132A1 (en) 1998-10-07
TW403736B (en) 2000-09-01
IL123195A (en) 2002-11-10
SG60203A1 (en) 1999-02-22
CN1197076A (zh) 1998-10-28
NZ329789A (en) 1999-09-29
US6077873A (en) 2000-06-20
AU723713B2 (en) 2000-09-07
AU5541298A (en) 1998-08-27
DE69801539D1 (de) 2001-10-11
CN101092442A (zh) 2007-12-26
HU9800373D0 (en) 1998-04-28
ATE205217T1 (de) 2001-09-15
DE69801539T2 (de) 2002-04-18
HU223755B1 (hu) 2005-01-28
CA2229960A1 (en) 1998-08-21
EP0869132B1 (en) 2001-09-05
HK1016188A1 (en) 1999-10-29
PL324939A1 (en) 1998-08-31
ID19947A (id) 1998-08-27
AR011680A1 (es) 2000-08-30
CN100522984C (zh) 2009-08-05
BR9800718B1 (pt) 2009-08-11
US6313180B1 (en) 2001-11-06
BR9800718A (pt) 1999-06-29
NO980737D0 (no) 1998-02-20
JP4392066B2 (ja) 2009-12-24
KR19980071540A (ko) 1998-10-26
IL123195A0 (en) 1998-09-24
HUP9800373A3 (en) 1999-06-28
TR199800282A1 (xx) 1998-09-21
CA2229960C (en) 2007-12-18
CZ50598A3 (cs) 1998-09-16
MX9801428A (es) 1998-12-31
DK0869132T3 (da) 2002-01-07

Similar Documents

Publication Publication Date Title
ES2113127T3 (es) Derivado de androstenona.
CU23241B7 (es) 2-fenil-1-(4(2-aminoetoxi)-benzil)-indol en combinacion con estrogenos
GT200000014A (es) Derivados de quinolin - 2 - ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
AR034858A1 (es) Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ES2164400T3 (es) Esteroides con actividad anticonceptiva y antiosteoporotica.
PA8494101A1 (es) Derivados heterociclicos utiles como agentes anticancerosos
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
PT748190E (pt) Metodos e formulacoes para uso no tratamento de disturbios ginecologicos benignos
BR9809703A (pt) Acilanilidas (hetero) ciclicamente substituìdas, não esteroidais, com eficácia gestagênica e androgênica mista
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
PA8480101A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
CR20120007A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
PA8547701A1 (es) Nucleosidos 4 substituidos.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
HN1998000157A (es) Agonistas de prostaglandinas
RU97104120A (ru) Фармацевтические композиции, содержащие производные эстра-1,3,5(10)-триена
HUP0100446A2 (hu) Dibenzilidén-szorbitot vagy annak származékát tartalmazó vízmentes gélkompozíciók és ilyen kompozíciókat magukban foglaló izzadásgátló kozmetikai készítmények
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
ES2189956T3 (es) Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 869132

Country of ref document: ES